Share Issue News

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 39,750 shares of the Company’s common stock at an exercise price per share of $8.11, which was the closing price on April 23, 2025 and re...

MINNEAPOLIS--(BUSINESS WIRE)--The Board of Directors of Ameriprise Financial, Inc. (NYSE: AMP) has announced the following: The company authorized an additional $4.5 billion for the repurchase of shares of its common stock during the period of April 24, 2025 through the close of business on June 30, 2027. As of April 23, 2025, the company had approximately $138 million available from its July 2023 authorization, which is available through September 30, 2025. The company intends to fund share re...

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announces a €14,999,998.59 capital increase subscribed by Sanofi. As announced on April 23, 2025, and given the satisfactory market conditions, Sanofi has agreed to subscribe to 8,345,387 new ordinary shares of Innate, at a price of €1.7974 per share, representing a total capital increase of €14,999,998.59 (€417,269.35 in nominal amount and €14,582,729.24 o...

FRANKLIN, Tenn.--(BUSINESS WIRE)--Community Health Systems, Inc. (the “Company”) (NYSE: CYH) announced today that its wholly owned subsidiary, CHS/Community Health Systems, Inc. (the “Issuer”), has commenced a cash tender offer (the “Tender Offer”) for any and all of its outstanding 6.875% Senior Unsecured Notes due 2028 (the “Notes”) on the terms and subject to the conditions set forth in the Issuer’s Offer to Purchase and Consent Solicitation Statement, dated April 23, 2025 (the “Offer to Pur...

DENVER--(BUSINESS WIRE)--Veritone, Inc. (NASDAQ: VERI), a leader in building human-centered enterprise AI solutions, today announced that the Compensation Committee of its Board of Directors granted an equity award on April 2, 2025 under its Inducement Grant Plan to one new employee, as an inducement material to her entering into employment with Veritone in accordance with Nasdaq Listing Rule 5635(c)(4). This equity award consists of restricted stock units representing the right to receive upon...

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Name of the Issuer Identity code of the Issuer Day of the transaction Identity code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS 529900JEHFM47DYY3S57 14/03/2025 FR0014000MR3 102,000 49.4276 XPAR EUROFINS 529900JEHFM47DYY3S57 14/03/2025 FR0014000MR3 40,000 49.5281 CEUX EUROFINS 529900JEHFM47DYY3S57 14/03/2025 FR0014000MR3 4,000...

GREENWICH, Conn.--(BUSINESS WIRE)--Eagle Point Credit Company Inc. (the “Company”) (NYSE: ECC) announced it has increased the continuous public offering of its 7.00% Series AA Convertible Perpetual Preferred Stock and 7.00% Series AB Convertible Perpetual Preferred Stock (collectively, the “Preferred Stock”) to up to 8,000,000 shares at a public offering price of $25 per share, for gross proceeds to the Company of $200 million. The Preferred Stock has a 7.00% annual dividend rate, paid monthly,...

NEW YORK--(BUSINESS WIRE)--Ares Acquisition Corporation II (NYSE: “AACT.U”, “AACT”, “AACT WS”) (“AACT” or the “Company”) announced today that as of the redemption deadline for the extraordinary general meeting of the Company (the “Meeting”), to be held today at 4:00 p.m. Eastern Time, to extend the period of time that the Company has to consummate a business combination (such period of time, the “Extension”), holders of 640,288 of the Company’s Class A ordinary shares, par value $0.0001 per sha...

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Caliber announced the closing of its underwritten public offering of total units for gross proceeds of approximately $900,000, before expenses....

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 121,500 common shares of the Company (the "Options"), with an effective grant date of April 21, 2025. The Options have an exercise price...